Neoplasms

Respiratory Tract (Lung and Bronchial) Diseases

All Conditions

Carcinoma, Non-Small-Cell Lung

Lung Neoplasms

Carcinoma

Respiratory Tract Neoplasms

Thoracic Neoplasms

Lung Diseases

Respiratory Tract Diseases

Carcinoma, Bronchogenic

Bronchial Neoplasms

All Drugs and Chemicals

Immunomodulating Agents

Immunologic Factors

The trial is designed as a prospective observational single arm study investigating stage IV non-small cell lung cancer patients who are routinely treated with a PD-1 inhibitor for indications approved by Health Canada. All patients who are selected will be referred for palliative thoracic radiotherapy and treated with a standard dose prescription of 30 Gy in 10 fractions.

Radiation combined with immunotherapy

Alex Sun, MD

Luke Heaphy, BSc

Study procedures include blood draw at baseline, end of radiation treatment, and at 1 month follow up visit.

Palliative Thoracic ImmunoRT

Evaluation of Toxicities With Thoracic Radiotherapy and Immune Checkpoint Inhibition in Non-small Cell Lung Cancer

rates of radiation-related toxicities in the combination of immunotherapy and palliative thoracic radiotherapy using CTCAE v5.0 grading

Patients will be followed for up to two years following the completion of their radiotherapy. They will undergo CT surveillance imaging as standard by routine immunotherapy protocol with a minimum of 3 scans at the 3, 6 and 12 month mark. Local and distant recurrence will be determined primarily by CTCAE with CT scans as per ir-RECIST v1.0 criteria.

University Health Network, Toronto

Study title	NCT ID	Conditions	Interventions	Eligibility	Organization	Link
Palliative Thoracic ImmunoRT	NCT03705806	Lung Cancer, No... Lung Cancer	Radiation combi...	18 Years -	University Health Network, Toronto
Palliative Thoracic ImmunoRT	NCT03705806	Lung Cancer, No... Lung Cancer	Radiation combi...	18 Years -	University Health Network, Toronto

Spots Global Cancer Trial Database for radiation combined with immunotherapy